GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ardelyx Inc (NAS:ARDX) » Definitions » Payments of Debt

ARDX (Ardelyx) Payments of Debt : $0.0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Ardelyx Payments of Debt?

Ardelyx's Payments of Debt for the three months ended in Dec. 2024 was $0.0 Mil.

Ardelyx's Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2024 was $0.0 Mil.


Ardelyx Payments of Debt Historical Data

The historical data trend for Ardelyx's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ardelyx Payments of Debt Chart

Ardelyx Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.13 -19.44 -33.04 - -

Ardelyx Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Ardelyx Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ardelyx Payments of Debt Related Terms

Thank you for viewing the detailed overview of Ardelyx's Payments of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Ardelyx Business Description

Traded in Other Exchanges
Address
400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Executives
Michael Raab director, officer: President & CEO 1119 ST PAUL STREET, BALTIMORE MD 21202
David M Mott director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Laura A Williams officer: Chief Medical Officer 116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Justin A Renz officer: Chief Financial Officer C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Elizabeth A Grammer officer: See Remarks 78TH FOURTH AVENUE, WALTHAM MA 02451
Robert Blanks officer: See Remarks C/O ARDELYX, 34175 ARDENWOOD BLVD., FREMONT CA 94555
David P. Rosenbaum officer: Chief Development Officer C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
Robert Ora Felsch officer: See Remarks C/O ARDELYX, INC., 34175 ARDENWOOD BLVD., FREMONT CA 94555
Susan Rodriguez officer: Chief Commercial Officer C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
Forest Baskett 10 percent owner
Scott D Sandell 10 percent owner
Jeffrey W Jacobs officer: VP, Chemistry C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
Muna Bhanji director C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Keith Santorelli officer: See Remarks C/O ARDELYX, INC. 34175 ARDENWOOD BLVD, FREMONT CA 94555
Onaiza Cadoret-manier director 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010